ProductUnclaimedDrug DiscoveryRNATherapeutics

Aptadir DiR Platform

by Aptadir Therapeutics

Gene-selective RNA inhibitors of DNMT1 for demethylating medicines

aptadir.com

Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.

About

Aptadir’s public platform centers on DNMTs Interacting RNAs (DiRs): modified RNA oligonucleotides that inhibit DNA methyltransferase 1 globally (aptaDiR) or at a locus (captaDiR) to reactivate silenced genes. The company is advancing candidates for genetic disorders and cancers based on this approach, as described on aptadir.com and in its September 2026 seed announcement.

Added via
web
Ownership
unclaimed

Where to go

For people

For agents

Nothing listed yet.

Product details

Product kind
Other

Use cases

Gene-selective demethylation therapeuticsFragile X and oncology pipeline research

Social profiles

← Directory